Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ian A.
Ian A. Mcalexander, Salt Lake City, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20120122840 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer. | 05-17-2012 |
Ian A. Stewart, Ventura, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100195650 | METHOD FOR SECURE RELIABLE POINT TO MULTI-POINT BI-DIRECTIONAL COMMUNICATIONS - Systems and methods for sending secure reliable point to multi-point communication on any communication infrastructure. The infrastructure is not required to conform to any specifications other than to be capable of point to point communications. The system consists of a protocol that allows for Secure Reliable point to multi-point communications irregardless of the support for such communications. This invention does not rely on the Internet or ATM or any other point to point or point to multi-point communications infrastructure. | 08-05-2010 |
Ian A. Wilson, Amersham GB
| Patent application number | Description | Published |
|---|---|---|
| 20110002849 | THERAPY SELECTION METHOD - The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo. | 01-06-2011 |
Ian A. Wilson, La Jolla, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090119019 | Small Molecule Mimetics of Erythropoietin - The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity. | 05-07-2009 |
| 20100250600 | Small Molecule Mimetics of Erythropoietin - The invention features computer-assisted methods for identifying molecules which will bind to the EPO receptor and act as an erythropoietin (EPO) mimetic. Preferred EPO mimetics identified using the method of the invention act as agonists of the EPO receptor in one or more in vitro or in vivo biological assays of EPO activity. | 09-30-2010 |
| 20110124842 | Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom - The present invention relates to the structure of Fab 4E10, e.g., as a complex with herein identified peptide KGND, herein identified as a 4E10 mimetope on gp41, as determined by crystallographic techniques, and the confirmation that peptide KGND has a functional relevant conformation, as well as the determination of key residues on 4E10, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides which bind to Fab 4E10. | 05-26-2011 |